|
1
|
Else T, Kim AC, Sabolch A, Raymond VM,
Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ and Hammer
GD: Adrenocortical carcinoma. Endocr Rev. 35:282–326. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertazza L, Barollo S, Mari ME, Faccio I,
Zorzan M, Redaelli M, Rubin B, Armanini D, Mian C and Pezzani R:
Biological effects of EF24, a curcumin derivative, alone or
combined with mitotane in adrenocortical tumor cell lines.
Molecules. 24:22022019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Libé R: Adrenocortical carcinoma (ACC):
Diagnosis, prognosis, and treatment. Front Cell Dev Biol. 3:452015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pianovski MAD, Maluf EM, de Carvalho DS,
Ribeiro RC, Rodriguez-Galindo C, Boffetta P, Zancanella P and
Figueiredo BC: Mortality rate of adrenocortical tumors in children
under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer.
47:56–60. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S,
Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, et
al: Adrenocortical carcinoma: Clinical outcomes and prognosis of
330 patients at a tertiary care center. Eur J Endocrinol.
169:891–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boulate G, Amazit L, Naman A, Seck A, Paci
A, Lombes A, Pussard E, Baudin E, Lombes M and Hescot S:
Potentiation of mitotane action by rosuvastatin: New insights for
adrenocortical carcinoma management. Int J Oncol. 54:2149–2156.
2019.PubMed/NCBI
|
|
7
|
Łebek-Szatańska A, Nowak KM and Papierska
L: Pitfalls in the diagnostics of aldosterone-producing
adre-nocortical carcinoma. Endokrynol Pol. 71:575–576. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubin B, Pilon C, Pezzani R, Rebellato A
and Fallo F: The effects of mitotane and 1α,25-dihydroxyvitamin
D3 on Wnt/beta-catenin signaling in human adrenocortical
carcinoma cells. J Endocrinol Invest. 43:357–367. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cusato J, De Francia S, Allegra S,
Carrella S, Pirro E, Piccione FM, De Martino F, Ferrero A, Daffara
FC, Terzolo M, et al: Circannual variation of mitotane and its
metabolites plasma levels in patients with adrenocortical
carcinoma. J Pharm Pharmacol. 69:1524–1530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Fu Q, Tang Y, Deng JH, Mei D and
Zhang B: A case report of neurological adverse events caused by
short-term and low-dose treatment of mi-totane: The role of
therapeutic drug monitoring. Medicine (Baltimore). 99:e226202020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hescot S, Seck A, Guerin M, Cockenpot F,
Huby T, Broutin S, Young J, Paci A, Baudin E and Lombès M:
Lipoprotein-free mitotane exerts high cytotoxic activity in
adrenocortical carcinoma. J Clin Endocrinol Metab. 100:2890–2898.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Almeida MQ, Bezerra-Neto JE, Mendonça BB,
Latronico AC and Fragoso MCBV: Primary malignant tumors of the
adrenal glands. Clinics (Sao Paulo). 73 (Suppl 1):e756s2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Frycz BA and Jagodzinski PP: Expression of
genes encoding steroidogenic enzymes and their role in prostate
carcinogenesis. J Med Sci. 83:73–80. 2014. View Article : Google Scholar
|
|
14
|
Paragliola RM, Torino F, Papi G, Locantore
P, Pontecorvi A and Corsello SM: Role of mitotane in adrenocortical
carcinoma-review and state of the art. Eur Endocrinol. 14:62–66.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hescot S, Amazit L, Lhomme M, Travers S,
DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, et
al: Identifying mitotane-induced mitochondria-associated membranes
dysfunctions: Metabolomic and lipidomic approaches. Oncotarget.
8:109924–109940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sbiera S, Leich E, Liebisch G, Sbiera I,
Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, et
al: Mitotane inhibits sterol-O-acyl transferase 1 triggering
lipid-mediated endoplasmic reticulum stress and apoptosis in
adrenocortical carcinoma cells. Endocrinology. 156:3895–3908. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Komarowska H, Bromińska B,
Janicka-Jedyńska M and Ruchała M: Adrenal incidentaloma: Nothing is
ever as it seems. Am J Med. 133:1048–1050. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo X, Mitra D, Sullivan RJ, Wittner BS,
Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT,
et al: Isolation and molecular characterization of circulating
melanoma cells. Cell Rep. 7:645–653. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weinstein D, Leininger J, Hamby C and
Safai B: Diagnostic and prognostic biomarkers in melanoma. J Clin
Aesthet Dermatol. 7:13–24. 2014.PubMed/NCBI
|
|
20
|
Wassermann JD, Novokmet A, Eichler-Jonsson
C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP and Malkin D:
Prevalence and functional consequence of P53 mutations in pediatric
adrenocortical carcinoma: A children's oncology group study. J Clin
Oncol. 33:602–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji Z, Njauw CN, Taylor M, Neel V, Flaherty
KT and Tsao H: P53 rescue through HDM2 antagonism suppresses
melanoma growth and potentiates MEK inhibition. J Invest Dermatol.
132:356–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lehmann TP, Wrzesiński T and Jagodziński
PP: The effect of mitotane on viability, steroidogenesis and gene
expression in NCI-H295R adrenocortical cells. Mol Med Rep.
7:893–900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dworakowska D, Drabarek A, Wenzel I,
Babińska A, Świątkowska-Stodulska R and Sworczak K: Adrenocortical
cancer (ACC)-literature overview and own experience. Endokrynol
Pol. 65:492–502. 2014.PubMed/NCBI
|
|
24
|
Sivandzade F, Bhalerao A and Cucullo L:
Analysis of the mitochondrial membrane potential using the cationic
JC-1 dyeas a sensitive fluorescent probe. Bio Protoc. 9:e31282019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stelcer E, Milecka P, Komarowska H, Jopek
K, Tyczewska M, Szyszka M, Lesniczak M, Suchorska W, Bekova K,
Szczepaniak B, et al: Adropin stimulates proliferation and inhibits
adrenocortial steroidogenesis in the human adrenal carcinoma
(HAC15) cell line. Front Endocrinol (Lausanne). 11:5613702020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szyszka M, Paschke L, Tyczewska M, Jopek
K, Celichowski P, Milecka P, Sultanova G, Stelcer E, Malinska A,
Malendowicz LK and Rucinski M: Analysis of transcriptome, selected
intracellular signaling pathways, proliferation and apoptosis of
LNCaP cells exposed to high leptin concentrations. Int J Mol Sci.
20:54122019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jopek K, Celichowski P, Szyszka M,
Tyczewska M, Milecka P, Malendowicz LK and Rucinski M:
Transcriptome profile of rat adrenal evoked by gonadectomy and
testosterone or estradiol replacement. Front Endocrinol (Lausanne).
8:262017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of affymetrix genechip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carvalho BS and Irizarry RA: A framework
for oligonucleotide microarray preprocessing. Bioinformatics.
26:2363–2367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fresno C and Fernández EA:
RDAVIDWebService: A versatile R interface to DAVID. Bioinformatics.
29:2810–2811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Benjamini Y and Cohen R: Weighted false
discovery rate controlling procedures for clinical trials.
Biostatistics. 18:91–104. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walter W, Sánchez-Cabo F and Ricote M:
GOplot: An R package for visually combining expression data with
functional analysis. Bioinformatics. 31:2912–2914. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Damian D and Gorfine M: Statistical
concerns about the GSEA procedure. Nat Genet. 36:6632004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sergushichev AA: An algorithm for fast
preranked gene set enrichment analysis using cumulative statistic
calculation. bioRxiv. Jun 20–2016.(Epub ahead of print).
|
|
38
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Isserlin R, Merico D, Voisin V and Bader
GD: Enrichment map-a Cytoscape app to visualize and explore OMICs
pathway enrichment results. F1000Res. 3:1412014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kucera M, Isserlin R, Arkhangorodsky A and
Bader GD: AutoAnnotate: A Cytoscape app for summarizing networks
with semantic annotations. F1000Res. 5:17172016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kolde R: J.R.p.v: Pheatmap: Pretty
Heatmaps. p6172012.
|
|
43
|
Deng M, Brägelmann J, Kryukov I,
Saraiva-Agostinho N and Perner S: FirebrowseR: An R client to the
broad institute's Firehose Pipeline. Database (Oxford).
2017:baw1602017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eaton A, Therneau T and Le-Rademacher J:
Designing clinical trials with (restricted) mean survival time
endpoint: Practical considerations. Clin Trials. 17:285–294. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu B, Mitra J, van den Heuvel S and Enders
GH: S and G2 phase roles for Cdk2 revealed by inducible expression
of a dominant-negative mutant in human cells. Mol Cell Biol.
21:2755–2766. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Dong W, Zhou H, Li H, Wang N,
Miao X and Jia L: α-2,8-Sialyltransferase is involved in the
development of multidrug resistance via PI3K/Akt pathway in human
chronic myeloid leukemia. IUBMB Life. 67:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fujita Y, Ito M and Ohsawa I:
Mitochondrial stress and GDF15 in the pathophysiology of sepsis.
Arch Biochem Biophys. 696:1086682020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li T, Su L, Lei Y and Liu X, Zhang Y and
Liu X: DDIT3 and KAT2A proteins regulate TNFRSF10A and TNFRSF10B
expression in endoplasmic reticulum stress-mediated apoptosis in
human lung cancer cells. J Biol Chem. 290:11108–11118. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Parmar J, Key RE and Rainey WE:
Development of an Adrenocorticotropin-responsive human
adrenocortical carcinoma cell line. J Clin Endocrinol Metab.
93:4542–4546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang T and Rainey WE: Human adrenocortical
cell lines. Mol Cell Endocrinol. 351:58–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Poli G, Guasti D, Rapizzi E, Fucci R, Canu
L, Bandini A, Cini N, Bani D, Mannelli M and Luconi M:
Morphofunctional effects of mitotane on mitochondria in human
adrenocortical cancer cells. Endocr Relat Cancer. 20:537–550. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Seidel E, Walenda G, Messerschmidt C,
Obermayer B, Peitzsch M, Wallace P, Bahethi R, Yoo T, Choi M,
Schrade P, et al: Generation and characterization of a
mitotane-resistant adrenocortical cell line. Endocr Connect.
9:122–134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bikas A, Jensen K, Patel A, Costello J,
Kaltsas G, Hoperia V, Wartofsky L, Burman K and Vasko V: Mitotane
induces mitochondrial membrane depolarization and apoptosis in
thyroid cancer cells. Int J Oncol. 55:7–20. 2019.PubMed/NCBI
|
|
55
|
Cerquetti L, Sampaoli C, Amendola D, Bucci
B, Misiti S, Raza G, De Paula U, Marchese R, Brunetti E, Toscano V
and Stigliano A: Mitotane sensitizes adrenocortical cancer cells to
ionizing radiations by involvement of the cyclin B1/CDK complex in
G2 arrest and mismatch repair enzymes modulation. Int J Oncol.
37:493–501. 2010.PubMed/NCBI
|
|
56
|
Cerquetti L, Bucci B, Carpinelli G, Lardo
P, Proietti A, Saporito R, Rindi G, Petrangeli E, Toscano V and
Stigliano A: Antineoplastic effect of a combined mitotane
treatment/ionizing radiation in adrenocortical carcinoma: A
preclinical study. Cancers (Basel). 11:17682019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Volante M, Terzolo M, Fassnacht M, Rapa I,
Germano A, Sbiera S, Daffara F, Sperone P, Scagliotti G, Allolio B,
et al: Ribonucleotide reductase large subunit (RRM1) gene
expression may predict efficacy of ad-juvant mitotane in
adrenocortical cancer. Clin Cancer Res. 18:3452–3461. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zsippai A, Szabó DR, Tömböl Z, Szabó PM,
Eder K, Pállinger E, Gaillard RC, Patócs A, Tóth S, Falus A, et al:
Effects of mitotane on gene expression in the adrenocortical cell
line NCI-H295R: A microarray study. Pharmacogenomics. 13:1351–1361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu Z, Sun Q and Wang X: PLK1, a potential
target for cancer therapy. Transl Oncol. 10:22–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang L, Zhu G, Wang X, Liao X, Huang R,
Huang C, Huang P, Zhang J and Wang P: Genomewide investigation of
the clinical significance and prospective molecular mechanisms of
kinesin family member genes in patients with lung adenocarcinoma.
Oncol Rep. 42:1017–1034. 2019.PubMed/NCBI
|
|
61
|
Li TF, Zeng HJ, Shan Z, Ye RY, Cheang TY,
Zhang YJ, Lu SH, Zhang Q, Shao N and Lin Y: Overexpression of
kinesin superfamily members as prognostic biomarkers of breast
cancer. Cancer Cell Int. 20:1232020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li X, Huang W, Huang W, Wei T, Zhu W, Chen
G and Zhang J: Kinesin family members KIF2C/4A/10/11/14/18B/20A/23
predict poor prognosis and promote cell proliferation in
hepatocellular carcinoma. Am J Transl Res. 12:1614–1639.
2020.PubMed/NCBI
|
|
63
|
Thangavelu PU, Lin CY, Vaidyanathan S,
Nguyen THM, Dray E and Duijf PHG: Overexpression of the E2F target
gene CENPI promotes chromosome instability and predicts poor
prognosis in estrogen receptor-positive breast cancer. Oncotarget.
8:62167–62182. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bendris N, Arsic N, Lemmers B and
Blanchard JM: Cyclin A2, Rho GTPases and EMT. Small GTPases.
3:225–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Phan NN, Wang CY, Li KL, Chen CF, Chiao
CC, Yu HG, Huang PL and Lin YC: Distinct expression of CDCA3,
CDCA5, and CDCA8 leads to shorter relapse free survival in breast
cancer patient. Oncotarget. 9:6977–6992. 2018. View Article : Google Scholar : PubMed/NCBI
|
